

# Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial)

NCT06392906

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Janjira Petsuksiri
Enrollment	68 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Patient with active moderate to severe thyroid eye disease with a CAS  $\geq 4$  with/ without diplopia before starting IVMP
- Patient with poor response to 3 doses of IVMP (CAS drop  $\leq 1$ ) ~~OR~~ CAS score  $\geq 3$  after 3 doses of IVMP
- Patients with diplopia after 3 doses of IVMP
- Patients with Graves' Ophthalmopathy who have maintained euthyroidism
- Non-pregnant adults (aged 35 years or older)

### Exclusion (1)

- Individuals with severe hypertension or diabetic retinopathy

## Locations (1 total)

---

Faculty of Medicine Siriraj Hospital Mahidol University, Bangkok Noi, Thailand